Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Follicular Lymphoma
Regimen:
DHAX (cytarabine + dexamethasone injection + oxaliplatin)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Second-line therapy and subsequent therapy for PTCL-NOS; EATL; MEITL, AITL, including nodal PTCL, TFH, and FTCL....Combination regimens...DHA (dexamethasone and cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login